Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Narcolepsy01:07

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: PANLAR consensus statement on biosimilars.

Clinical rheumatology·2019
Same author

PANLAR consensus statement on biosimilars.

Clinical rheumatology·2019
Same author

Urinary biomarkers for lupus nephritis: the role of the vascular cell adhesion molecule-1.

Lupus·2019
Same author

Immunogenetic profiling of 23 SNPs of cytokine and chemokine receptor genes through a minisequencing technique: Design, development and validation.

International journal of immunogenetics·2017
Same author

Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis.

Genetics and molecular research : GMR·2016
Same author

Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus.

Lupus·2016

Related Experiment Video

Updated: Jun 24, 2026

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

Glu298Asp eNOS polymorphism is not associated with SLE.

T Mucenic1, J C T Brenol, M Bredemeier

  • 1Medical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS).

Lupus
|March 26, 2009
PubMed
Summary

The endothelial nitric oxide synthase (eNOS) Glu298Asp polymorphism is not associated with systemic lupus erythematosus (SLE) susceptibility or its clinical features. This genetic variant does not appear to play a significant role in SLE development or manifestations.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Related Experiment Videos

Last Updated: Jun 24, 2026

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Area of Science:

  • Genetics
  • Rheumatology
  • Molecular Biology

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a poorly understood genetic basis.
  • Endothelial nitric oxide synthase (eNOS) plays a crucial role in vascular function and inflammation.
  • The Glu298Asp polymorphism in the eNOS gene has been investigated for its potential role in various diseases.

Purpose of the Study:

  • To investigate the association between the eNOS Glu298Asp polymorphism and susceptibility to SLE.
  • To evaluate the relationship between the eNOS Glu298Asp polymorphism and clinical manifestations of SLE, including lupus nephritis, antiphospholipid syndrome, and cardiovascular disease.

Main Methods:

  • Genotyping by polymerase chain reaction (PCR) was performed for the eNOS Glu298Asp polymorphism.
  • A cohort of 113 SLE patients and 206 healthy controls of European ancestry were analyzed.
  • Clinical, demographic, and laboratorial data were collected and analyzed for associations with specific genotypes.

Main Results:

  • No significant differences were observed in the allelic or genotypic distribution of the eNOS Glu298Asp polymorphism between SLE patients and healthy controls.
  • The polymorphism showed no association with lupus nephritis, antiphospholipid syndrome, or cardiovascular disease in SLE patients.
  • Statistical power was low for evaluating associations with clinical manifestations.

Conclusions:

  • The eNOS Glu298Asp polymorphism does not appear to be a major genetic factor in SLE susceptibility.
  • This polymorphism is not significantly associated with key clinical manifestations of SLE.
  • Further studies with larger cohorts may be needed to definitively rule out a minor role in clinical expression.